Skip to Content
Biotechnology

The chart that shows how we’ll get back to normal

After a year of grim milestones, the data from Pfizer’s vaccine trial will be the good news we’ll remember.
December 10, 2020
margaret gets Pfizer vaccine
margaret gets Pfizer vaccine
Margaret Keenan, 90, is applauded by staff as she returns to her ward after becoming the first person in the United Kingdom to receive the Pfizer/BioNtech covid-19 vaccine at University Hospital at the start of the largest ever immunisation programme in the UK's historyJacob King - Pool / Getty Images

A covid-19 chart that’s been shared thousands of times is dramatizing just how well vaccines against the disease can work and how we might get out of pandemic hell.

Today, advisors to the US Food and Drug Administration voted in favor of emergency authorization for Pfizer’s covid-19 shot, and the data in this chart is a big reason why.

The graphic (below), released by Pfizer and its partner, BioNTech, shows the difference in covid-19 infection rates between the people in their trial who got a novel gene vaccine and those who got a placebo.

Vaccines work
PFIZER/BIONTECH/NEJM

The volunteers who were given a placebo shot appear as the blue line. The ones who got a vaccine are in red. Each time either line jumps up, that’s when a new covid-19 case occurred.

What the data shows is that during the first week after getting their shots, both groups of people kept getting covid-19 at about the same rate. But after that, the lines start to separate. And they just keep separating and separating.

That’s the result of the vaccine taking effect, which usually takes a few days and gets boosted by a second dose. After two weeks, hardly anyone with the vaccine was getting covid-19. But the disease kept striking those who got the placebo with clockwork regularity.

“No comment. This is what vaccines do,” said Florian Krammer, a prominent immunologist, who posted a version of the image to Twitter.

The triumphalism is justified. This is what the researchers have been working toward all year. And the data in this graphic leaves no room for rumors, politics, or uninformed commentary. It’s as plain as day: this vaccine is one of the best we’ve ever seen.

Pfizer presented the chart in a paper published on December 10 in the New England Journal of Medicine and earlier in the week as part of its application to the US Food and Drug Administration to begin selling the vaccine. That authorization could be given at any moment now that the agency’s advisors have voted in favor.

The stark nature of Pfizer’s proof will be more important than ever as the vaccine starts to reach clinics and hospitals. Anti-vaccination forces are shouting through bullhorns on social media to stir fears over the shot, and even ordinary people are wondering if they should get it.

Researchers have known all along that vaccines can rapidly turn infectious diseases from scourges to bad memories. Since they were first developed, and especially during the 20th century, the transformative effects of vaccines have been witnessed again and again.

These charts from Our World in Data show what happened after the introduction of the vaccines for polio and measles. Polio put kids in iron lungs and scared parents away from pools. Then, in a matter of a few years, the fear was gone.

Vaccine triumphs
OUR WORLD IN DATA/MAX ROSER

There are still unknowns. How long does protection from covid-19 last? No one knows; there have been encouraging signs recently that immunity may last years in people who have had the disease, but it’s too early to say for certain. Moreover, limited supplies mean that, at least in the US, much of the public won’t get a vaccine until toward the middle of 2021. It could be 2022 before most of the world is vaccinated, according to the World Health Organization.

Since the beginning of the pandemic, case curves and death curves have been our daily reminder that it isn’t over—and lately, that it’s getting worse. The phrase “grim milestone” shows up regularly in news reports. More than 3,000 Americans died in a single day this week from covid-19.

Pfizer’s chart is the antidote to those death curves. It shows how we can get off the roller coaster. As people become vaccinated with its shot (or those from other companies), more and more of us will be living on the safe and protected red curve, not the fearful blue one where covid-19 can strike at any time.

This is the graphic of the year. It’s what getting back to normal looks like.

Deep Dive

Biotechnology

transplant surgery
transplant surgery

The gene-edited pig heart given to a dying patient was infected with a pig virus

The first transplant of a genetically-modified pig heart into a human may have ended prematurely because of a well-known—and avoidable—risk.

Muhammad bin Salman funds anti-aging research
Muhammad bin Salman funds anti-aging research

Saudi Arabia plans to spend $1 billion a year discovering treatments to slow aging

The oil kingdom fears that its population is aging at an accelerated rate and hopes to test drugs to reverse the problem. First up might be the diabetes drug metformin.

individual aging affects covid outcomes concept
individual aging affects covid outcomes concept

Anti-aging drugs are being tested as a way to treat covid

Drugs that rejuvenate our immune systems and make us biologically younger could help protect us from the disease’s worst effects.

Workers disinfect the street outside Shijiazhuang Railway Station
Workers disinfect the street outside Shijiazhuang Railway Station

Why China is still obsessed with disinfecting everything

Most public health bodies dealing with covid have long since moved on from the idea of surface transmission. China’s didn’t—and that helps it control the narrative about the disease’s origins and danger.

Stay connected

Illustration by Rose WongIllustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.